Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,301 INR
Change Today +37.60 / 2.98%
Volume 49.0K
AJP On Other Exchanges
Symbol
Exchange
Natl India
As of 1:13 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

ajanta pharma ltd (AJP) Snapshot

Open
1,278
Previous Close
1,263
Day High
1,310
Day Low
1,267
52 Week High
04/8/15 - 1,475
52 Week Low
05/5/14 - 392.80
Market Cap
114.4B
Average Volume 10 Days
141.7K
EPS TTM
26.62
Shares Outstanding
87.9M
EX-Date
07/24/14
P/E TM
48.9x
Dividend
4.00
Dividend Yield
0.32%
Current Stock Chart for AJANTA PHARMA LTD (AJP)

Related News

No related news articles were found.

ajanta pharma ltd (AJP) Related Businessweek News

No Related Businessweek News Found

ajanta pharma ltd (AJP) Details

Ajanta Pharma Limited, a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products worldwide. The company provides its products in anti-malarial, cardiovascular, dermatology, male erectile dysfunction, musculoskeletal, orthopedic, gynecology, pediatric, general health, anti-biotic, respiratory, and ophthalmology therapeutic areas. The company offers its cardiovascular products for the treatment of atherothrombosis, coronary artery diseases, dyslipidemia, hypertension, and heart failure under 27 brands; dermatology products in various areas, including acne, alopecia, dermatitis/eczema, skin infections, moisturizers, pigment disorders, psoriasis, scars, and sunscreens under 48 brands; and ophthalmology products for allergies, dry eye, glaucoma, eye infections, inflammation, macular degeneration, and retinopathies under 54 brands. It also develops products for bile acid induced diseases, gastric acid-related diseases, gout, muscle relaxant, pain and inflammation, constipation, neuropathic pain, nausea and vomiting, and vertigo; and pain management products under 31 brands. The company provides its products in various dosage forms comprising tablets, capsules, powders, ophthalmic sterile eye drops, ointments, and injectables. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Founded in 1973

ajanta pharma ltd (AJP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ajanta pharma ltd (AJP) Key Developments

Ajanta Pharma Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Ajanta Pharma Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported total income from operations of INR 3,625.7 million against INR 3,008.5 million for the same period in the last year. Net sales were INR 3,562.8 million against INR 2,925.9 million for the same period in the last year. Profit from operations before other income, finance costs and tax was INR 1,188.2 million against INR 877.3 million a year ago. Profit from ordinary activities before tax was INR 1,238.9 million against INR 895.8 million for the same period in the last year. Net profit was INR 847.1 million or INR 24.06 per diluted share against INR 624.2 million or INR 17.72 per diluted share before and after extraordinary items for the same period in the last year. EBITDA was at INR 1,310 million compared to INR 990 million, growth of 32% over third quarter last year. Exports contributed 62% of the total operating income for the quarter. For nine months, the company reported total income from operations of INR 9,873.6 million against INR 7,988.7 million for the same period in the last year. Net sales were INR 9,682.6 million against INR 7,787.3 million for the same period in the last year. Profit from operations before other income, finance costs and tax was INR 2,950.1 million against INR 2,066.4 million a year ago. Profit from ordinary activities before tax was INR 3,258.7 million against INR 2,225.8 million for the same period in the last year. Net profit was INR 2,220.6 million or INR 63.07 per diluted share against INR 1,507.7 million or INR 42.82 per diluted share for the same period in the last year. EBITDA was at INR 3,320 million compared to INR 2,340 million, growth of 42% over third quarter last year. Exports contributed 61% of the total operating income for the period.

Ajanta Pharma Ltd. to Report Q3, 2015 Results on Jan 28, 2015

Ajanta Pharma Ltd. announced that they will report Q3, 2015 results on Jan 28, 2015

Ajanta Pharma Ltd., Board Meeting, Jan 28, 2015

Ajanta Pharma Ltd., Board Meeting, Jan 28, 2015. Agenda: To consider and approve, inter alia, the unaudited financial results for the third quarter ended December 31, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AJP:IN 1,300.60 INR +37.60

AJP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Glenmark Pharmaceuticals Ltd 898.20 INR +7.90
Indoco Remedies Ltd 359.40 INR +10.30
Sun Pharmaceutical Industries Ltd 947.20 INR +8.35
Unichem Laboratories Ltd 209.25 INR +4.75
View Industry Companies
 

Industry Analysis

AJP

Industry Average

Valuation AJP Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AJANTA PHARMA LTD, please visit www.ajantapharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.